Ken Griffin Novo Cure LTD Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Cure LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 894,148 shares of NVCR stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
894,148
Previous 90,000
893.5%
Holding current value
$10.1 Million
Previous $1.6 Million
892.83%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding NVCR
# of Institutions
283Shares Held
77.5MCall Options Held
943KPut Options Held
155K-
Black Rock Inc. New York, NY12.1MShares$138 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$122 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.9MShares$78.3 Million9.53% of portfolio
-
Capital World Investors Los Angeles, CA6.38MShares$72.4 Million0.02% of portfolio
-
State Street Corp Boston, MA2.68MShares$30.4 Million0.0% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.19B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...